Table 1 Patient Demographics and disease characteristics within study population.
Characteristic | Value (%) | |
|---|---|---|
n = 18 | ||
Sex | ||
Male | 6 (33%) | |
Female | 12 (67%) | |
Race | ||
White | 15 (83%) | |
Black | 3 (17%) | |
Age at First Diagnosis (mean ± SD) | 62.7 ± 8.4 years | |
ECOG | ||
0 | 6 (33%) | |
1 | 12 (67%) | |
Myeloma Type | ||
IgG | 15 (83%) | |
IgA | 3 (17%) | |
Kappa/Lambda | ||
Kappa | 14 (78%) | |
Lambda | 4 (22%) | |
Stage (ISS) | ||
I | 2 (11%) | |
II | 12 (67%) | |
III | 4 (22%) | |
Pre-HCT Exposure | ||
Lenalidomide | 18 (100%) | |
Alkylating Agent | 2 (11%) | |
Topoisomerase | 0 (0%) | |
Leukemia Type | ||
AML | 8 (44%) | |
APML | 1 (6%) | |
B-ALL | 9 (50%) | |
Top Recurrent Mutations | ||
DNMT3A | 6 (33%) | |
TP53 | 5 (28%) | |
ETV6 | 4 (22%) | |
RUNX1 | 4 (22%) | |
GATA2 | 3 (17%) | |
NOTCH2 | 3 (17%) | |
